Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 12-Month High – Time to Buy?

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) reached a new 52-week high on Tuesday . The company traded as high as $44.53 and last traded at $44.19, with a volume of 61355 shares. The stock had previously closed at $43.20.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on KNSA. The Goldman Sachs Group lifted their price objective on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Wedbush raised their price objective on shares of Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Thursday. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 2nd. Finally, Citigroup upped their price objective on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a report on Friday, October 17th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $52.33.

Kiniksa Pharmaceuticals International Trading Up 2.8%

The company has a 50 day moving average of $41.50 and a 200 day moving average of $37.39. The firm has a market cap of $3.37 billion, a price-to-earnings ratio of 98.68 and a beta of 0.04.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, October 28th. The company reported $0.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The business had revenue of $180.86 million during the quarter, compared to the consensus estimate of $166.64 million. During the same quarter last year, the company earned ($0.18) earnings per share. The firm’s revenue was up 61.2% compared to the same quarter last year. Equities analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Insider Activity at Kiniksa Pharmaceuticals International

In other news, CFO Mark Ragosa sold 42,841 shares of the stock in a transaction on Monday, December 8th. The shares were sold at an average price of $41.49, for a total transaction of $1,777,473.09. Following the completion of the sale, the chief financial officer owned 31,086 shares of the company’s stock, valued at $1,289,758.14. This represents a 57.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John F. Paolini sold 82,542 shares of the business’s stock in a transaction on Friday, October 31st. The shares were sold at an average price of $37.14, for a total transaction of $3,065,609.88. Following the completion of the sale, the insider directly owned 61,324 shares in the company, valued at $2,277,573.36. This represents a 57.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 202,130 shares of company stock worth $8,019,579. Corporate insiders own 53.48% of the company’s stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. EverSource Wealth Advisors LLC boosted its position in Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after acquiring an additional 532 shares during the last quarter. Mariner LLC boosted its holdings in Kiniksa Pharmaceuticals International by 5.8% during the third quarter. Mariner LLC now owns 13,253 shares of the company’s stock worth $515,000 after purchasing an additional 732 shares during the last quarter. CWM LLC boosted its holdings in Kiniksa Pharmaceuticals International by 3.9% during the fourth quarter. CWM LLC now owns 20,605 shares of the company’s stock worth $850,000 after purchasing an additional 764 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its position in Kiniksa Pharmaceuticals International by 4.9% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 16,424 shares of the company’s stock valued at $701,000 after purchasing an additional 771 shares in the last quarter. Finally, USA Financial Formulas acquired a new stake in Kiniksa Pharmaceuticals International in the 3rd quarter valued at $32,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.